Biopharma

Human medicines European public assessment report (EPAR): Kentera (previously Oxybutynin Nicobrand), oxybutynin, Date of authorisation: 15/06/2004, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Kentera (previously Ox...

Human medicines European public assessment report (EPAR): Azilect, rasagiline, Date of authorisation: 21/02/2005, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Azilect, rasagiline, D...

Congressional commission urges $15B, more action to maintain US biotech advantage over China

Congressional commission urges $15B, more action to mai...

Apr 8, 2025 0

A U.S. congressional commission has made the case for “swift action” to maintain...

STAT+: As more patients get automated test results, researchers seek ways to calm their nerves

STAT+: As more patients get automated test results, res...

Apr 8, 2025 0

Editor's note: This story contains a description of self-harm. Oncologist Mark L...

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 October 2025, 09:30 (CEST) to 17 October 2025, 13:30 (CEST)

EMA roundtable with stakeholders on the 20th anniversar...

Apr 8, 2025 0

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, ...

J&J links FcRn blocker to sustained benefits as FDA ruling on potential blockbuster nears

J&J links FcRn blocker to sustained benefits as FDA rul...

Apr 8, 2025 0

Johnson & Johnson has reinforced a key plank of its plan to build nipocalimab in...

Third Rock-backed Merida launches with $121M series A to fund autoimmune pipeline

Third Rock-backed Merida launches with $121M series A t...

Apr 8, 2025 0

The latest biotech to roll out of Third Rock Ventures is working on Fc-based the...

As Trump threatens tariffs on drugs, industry warns EU of $100B-plus pharma exodus to US

As Trump threatens tariffs on drugs, industry warns EU ...

Apr 8, 2025 0

Although President Trump’s “Liberation Day” tariffs have spared pharmaceuticals,...

Human medicines European public assessment report (EPAR): Pregabalin Viatris Pharma (previously Pregabalin Pfizer), pregabalin, Date of authorisation: 10/04/2014, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Pregabalin Viatris Pha...

Fierce Biotech Fundraising Tracker '25: Merida debuts with $121M; RayThera raises $110M series A

Fierce Biotech Fundraising Tracker '25: Merida debuts w...

Apr 8, 2025 0

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

Human medicines European public assessment report (EPAR): Refixia, nonacog beta pegol, Date of authorisation: 02/06/2017, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Refixia, nonacog beta ...

Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sugammadex, Date of authorisation: 26/05/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sug...

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Enspryng, satralizumab...

Human medicines European public assessment report (EPAR): Ontozry, cenobamate, Date of authorisation: 26/03/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Ontozry, cenobamate, D...

Novo Nordisk plugs more than $1B into upgrade of Brazilian manufacturing operations for injectable drugs, including GLP-1s

Novo Nordisk plugs more than $1B into upgrade of Brazil...

Apr 8, 2025 0

Looking to grow production in Latin America’s biggest country, Novo Nordisk is c...

Fierce Biotech Layoff Tracker 2025: Lyell lets go of 73 workers; Relay sheds staff again

Fierce Biotech Layoff Tracker 2025: Lyell lets go of 73...

Apr 8, 2025 0

As always, if you know of layoffs occurring at a biotech, please reach out to th...

STAT+: Pharmalittle: We’re reading about a plan to boost U.S. biotech funding, FDA user fees, and more

STAT+: Pharmalittle: We’re reading about a plan to boos...

Apr 8, 2025 0

A federal commission is calling for $15 billion in new financing to reinforce U....

STAT+: With Trump review, a Harvard infectious disease researcher stands to lose it all

STAT+: With Trump review, a Harvard infectious disease ...

Apr 8, 2025 0

"This looks bad"’ A Harvard infectious disease researcher is targeted in Preside...

Cartesian’s CAR-T may help autoimmune patients long term

Cartesian’s CAR-T may help autoimmune patients long term

Apr 8, 2025 0

The biotech news stories you gotta read this morning, brought to you by The Read...

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Date of authorisation: 08/05/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Qarziba (previously Di...

Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint

Rallybio abandons lead program after phase 2 data in ra...

Apr 8, 2025 0

Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, th...

Are Republicans changing course on Medicare Advantage?

Are Republicans changing course on Medicare Advantage?

Apr 8, 2025 0

The health news you need to read this morning.

Human medicines European public assessment report (EPAR): Evrenzo, roxadustat, Date of authorisation: 18/08/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025 0

Human medicines European public assessment report (EPAR): Evrenzo, roxadustat, D...

KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal

KalVista, awaiting FDA call on HAE drug, sells Japanese...

Apr 8, 2025 0

As KalVista Pharmaceuticals awaits an FDA decision on sebetralstat, the company ...

26
27
28
29
30

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.